Anti-Human CD11a (Efalizumab) - Dylight 488

Antibody Details

Product Details

Reactivity Species

Human

Host Species

Human

Expression Host

HEK-293

FC Effector Activity

Active

Immunogen

Human CD11a

Product Concentration

0.2 mg/ml

Formulation

This DyLight® 488 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.

Storage and Handling

This DyLight® 488 conjugate is stable when stored at 2-8°C. Do not freeze.

Regulatory Status

Research Use Only (RUO). Non-Therapeutic.

Country of Origin

USA

Shipping

Next Day 2-8°C

Excitation Laser

Blue Laser (493 nm)

RRID

AB_2894028

Applications and Recommended Usage?
Quality Tested by Leinco

FC The suggested concentration for Efalizumab biosimilar antibody for staining cells in flow cytometry is ≤ 1.0 μg per 10⁶ cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application.

Other Applications Reported In Literature ?

FA
IHC
CyTOF®

Additional Reported Applications For Relevant Conjugates ?

B
ELISA

Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity

This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Efalizumab. Clone hu1124 recognizes human CD11a. This product is for research use only.

Antigen Distribution

CD11a is expressed on all leukocytes.

Background

CD11a and CD18 are the Integrin alpha-L and beta-2 subunits that combine to form LFA-1, a glycoprotein and a member of the Integrin family. The Integrin alpha-L/beta-2 complex is a receptor for ICAM1, ICAM2, ICAM3, ICAM4 and F11R. LFA-1 participates in the immunological synapses between CD8+ T lymphocytes and antigen-presenting cells. Efalizumab binds to the CD11a subunit of LFA-1 and acts as an immunosuppressant by inhibiting lymphocyte activation and cell migration out of blood vessels into tissues. Anti-Human CD11a (Efalizumab) utilizes the same variable regions from the therapeutic antibody Efalizumab making it ideal for research projects.

Antigen Details

Protein

CD11a

PubMed

CD11a

NCBI Gene Bank ID

3683

UniProt.org

Information on Uniprot.org

Research Area

Cell Adhesion

.

Cell Biology

.

Costimulatory Molecules

.

Immunology

.

Innate Immunity

.

Neuroinflammation

.

Neuroscience

References & Citations

1. Gottlieb, AB. et al. (2002) Arch Dermatol. 138(5):591-600.

Technical Protocols